Quince Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Quince Therapeutics generated cash of -$18,292,000, which is more than the previous year. Cash used in financing activities reached the amount of $143,000 last year. Net change in cash is therefore -$23,827,000.
Cash Flow
| 2017 | -9.82M | -77K | 7.75M |
|---|---|---|---|
| 2018 | -11.69M | -46.75M | 75.92M |
| 2019 | -33.27M | -17.74M | 77.36M |
| 2020 | -50.81M | -52.43M | 118.87M |
| 2021 | -62.93M | 58.95M | 6.80M |
| 2022 | -44.03M | 18.00M | 707K |
| 2023 | -18.29M | -5.75M | 143K |
QNCX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 44.57M | 69.72M | 66.84M | 51.21M | 24.87M | 7.39M | 9.54M |
Operating activities | |||||||
Net income | -31.38M | -51.66M | -89.94M | -76.84M | -36.98M | -12.47M | -12.23M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 322K | 204K | 344K | 332K | 188K | 51K | 45K |
Stock-based compensation expense | 5.22M | 16.61M | 29.85M | 14.47M | 2.05M | 0 | 38K |
| Deferred income tax benefit | 5.22M | 16.61M | 29.85M | 14.47M | 2.05M | 0 | 38K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -288K | -5.94M | 1.35M | 480K | 2.58M | -23K | 223K |
Cash generated by operating activities | -18.29M | -44.03M | -62.93M | -50.81M | -33.27M | -11.69M | -9.82M |
Investing activities | |||||||
Purchases Of Investments | -113.78M | -75.02M | -38.78M | -187.14M | -135.41M | -55.24M | 0 |
Investments In Property Plant And Equipment | -160K | -133K | -180K | -52K | -55K | -212K | -77K |
Acquisitions Net | -2.11M | 10.59M | -58.95M | 52.43M | -812K | 0 | 0 |
Cash generated by investing activities | -5.75M | 18.00M | 58.95M | -52.43M | -17.74M | -46.75M | -77K |
Financing activities | |||||||
Common Stock Issued | 149K | 608K | 6.80M | 118.91M | 77.82M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 63.73M | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -6K | -49K | 0 | -34K | -559K | 0 | 7.75M |
Cash used in financing activities | 143K | 707K | 6.80M | 118.87M | 77.36M | 75.92M | 7.75M |
Net Change In Cash | -23.82M | -25.14M | 2.88M | 15.62M | 26.34M | 17.47M | -2.15M |
Cash at end of period | 20.75M | 44.57M | 69.72M | 66.84M | 51.21M | 24.87M | 7.39M |
| Data source | Data source | Data source | Data source | Data source |